WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Hofseth BioCare ASA
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact, Medical
Synthego | March 17, 2023
Synthego Corp., a leading genome engineering solutions provider, announced today the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services. The ecosystem brings together high-value partners including Arctoris, BrainXell, Curia, PhenoVista, and Pluristyx to offer a coordinated solution for CRISPR-driven drug discovery. The CR...
Cell and Gene Therapy
I-Mab | July 12, 2021
I-Mab, a clinical-stage biopharmaceutical business dedicated to discovering, developing, and commercialization of novel biologics, announced today the signing of two new partnerships with Chinese emerging biotech firms to enhance its next-generation innovation pipeline. Collaborations with Immorna, an mRNA biotech company, and neoX Biotech, an AI-enabled R&D biotech company, provide I-Mab access to revolutionary technologies to search for new cancer treatments. I-Mab will crea...
Research
Celyad Oncology SA | December 09, 2021
Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...
MedTech, Industrial Impact
Ribbon Biolabs | December 21, 2022
Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...
Industrial Impact
Whitepaper
Cell and Gene Therapy, Industrial Impact
Cell and Gene Therapy, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE